IMPORTANCE: Few rigorous clinical trials have investigated the effectiveness of exercise on the physical functioning of patients with Alzheimer disease (AD). OBJECTIVES: To investigate the effects of intense and long-term exercise on the physical functioning and mobility of home-dwelling patients with AD and to explore its effects on the use and costs of health and social services. DESIGN: A randomized controlled trial. SETTING AND PARTICIPANTS: A total of 210 home-dwelling patients with AD living with their spousal caregiver. INTERVENTIONS: The 3 trial arms included (1) group-based exercise (GE; 4-hour sessions with approximately 1-hour training) and (2) tailored home-based exercise (HE; 1-hour training), both twice a week for 1 year, and (3) a control group (CG) receiving the usual community care. MAIN OUTCOME MEASURES: The Functional Independence Measure (FIM), the Short Physical Performance Battery, and information on the use and costs of social and health care services. RESULTS: All groups deteriorated in functioning during the year after randomization, but deterioration was significantly faster in the CG than in the HE or GE group at 6 (P = .003) and 12 (P = .015) months. The FIM changes at 12 months were -7.1 (95% CI, -3.7 to -10.5), -10.3 (95% CI, -6.7 to -13.9), and -14.4 (95% CI, -10.9 to -18.0) in the HE group, GE group, and CG, respectively. The HE and GE groups had significantly fewer falls than the CG during the follow-up year. The total costs of health and social services for the HE patient-caregiver dyads (in US dollars per dyad per year) were $25,112 (95% CI, $17,642 to $32,581) (P = .13 for comparison with the CG), $22,066 in the GE group ($15,931 to $28,199; P = .03 vs CG), and $34,121 ($24,559 to $43,681) in the CG. CONCLUSIONS AND RELEVANCE: An intensive and long-term exercise program had beneficial effects on the physical functioning of patients with AD without increasing the total costs of health and social services or causing any significant adverse effects. TRIAL REGISTRATION: anzctr.org.au Identifier: ACTRN12608000037303.
RCT Entities:
IMPORTANCE: Few rigorous clinical trials have investigated the effectiveness of exercise on the physical functioning of patients with Alzheimer disease (AD). OBJECTIVES: To investigate the effects of intense and long-term exercise on the physical functioning and mobility of home-dwelling patients with AD and to explore its effects on the use and costs of health and social services. DESIGN: A randomized controlled trial. SETTING AND PARTICIPANTS: A total of 210 home-dwelling patients with AD living with their spousal caregiver. INTERVENTIONS: The 3 trial arms included (1) group-based exercise (GE; 4-hour sessions with approximately 1-hour training) and (2) tailored home-based exercise (HE; 1-hour training), both twice a week for 1 year, and (3) a control group (CG) receiving the usual community care. MAIN OUTCOME MEASURES: The Functional Independence Measure (FIM), the Short Physical Performance Battery, and information on the use and costs of social and health care services. RESULTS: All groups deteriorated in functioning during the year after randomization, but deterioration was significantly faster in the CG than in the HE or GE group at 6 (P = .003) and 12 (P = .015) months. The FIM changes at 12 months were -7.1 (95% CI, -3.7 to -10.5), -10.3 (95% CI, -6.7 to -13.9), and -14.4 (95% CI, -10.9 to -18.0) in the HE group, GE group, and CG, respectively. The HE and GE groups had significantly fewer falls than the CG during the follow-up year. The total costs of health and social services for the HEpatient-caregiver dyads (in US dollars per dyad per year) were $25,112 (95% CI, $17,642 to $32,581) (P = .13 for comparison with the CG), $22,066 in the GE group ($15,931 to $28,199; P = .03 vs CG), and $34,121 ($24,559 to $43,681) in the CG. CONCLUSIONS AND RELEVANCE: An intensive and long-term exercise program had beneficial effects on the physical functioning of patients with AD without increasing the total costs of health and social services or causing any significant adverse effects. TRIAL REGISTRATION: anzctr.org.au Identifier: ACTRN12608000037303.
Authors: Lauren T Ptomey; Eric D Vidoni; Esteban Montenegro-Montenegro; Michael A Thompson; Joseph R Sherman; Anna M Gorczyca; Jerry L Greene; Richard A Washburn; Joseph E Donnelly Journal: J Aging Phys Act Date: 2019-09-01 Impact factor: 1.961
Authors: M H Suominen; T M Puranen; S K Jyväkorpi; U Eloniemi-Sulkava; H Kautiainen; U Siljamäki-Ojansuu; K H Pitkalä Journal: J Nutr Health Aging Date: 2015-11 Impact factor: 4.075
Authors: Lauren T Ptomey; Amanda N Szabo-Reed; Eric D Vidoni; Richard A Washburn; Anna M Gorczyca; Todd D Little; Jaehoon Lee; Brian C Helsel; Kristine N Williams; Joseph E Donnelly Journal: Contemp Clin Trials Date: 2020-09-23 Impact factor: 2.226
Authors: Niko M Perttila; Hanna Öhman; Timo E Strandberg; Hannu Kautiainen; Minna Raivio; Marja-Liisa Laakkonen; Niina Savikko; Reijo S Tilvis; Kaisu H Pitkälä Journal: Drugs Aging Date: 2018-11 Impact factor: 3.923